Exosomes Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight's comprehensive report today! @ Exosomes Pipeline Outlook
Key Takeaways from the Exosomes Pipeline Report
In April 2025, Aegle Therapeutics announced a study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks.
DelveInsight's Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.
Promising Exosomes Pipeline Therapies such as Anlotinib, AGLE 102, TISSEEL, and others.
Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs
Exosomes Emerging Drugs Profile
ExoFlo: Direct Biologics
ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation.
EXO-CD24: Nano24
EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created.
AGLE-102: Aegle Therapeutics
AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.
Progenza: Cambium Bio
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types.
EV-101: EV Therapeutics
EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.
The Exosomes Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market
Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight's detailed report now! @ New Exosomes Drugs
Exosomes Companies
Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.
Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Exosomes Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Exosomes Market Drivers and Barriers
Scope of the Exosomes Pipeline Report
Coverage- Global
Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.
Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others.
Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Exosomes : Overview
Pipeline Therapeutics
Therapeutic Assessment
Exosomes – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
CAP-1002: Capricor Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Progenza: Regeneus
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
AGLE 102: Aegle Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Exosomes Key Companies
Exosomes Key Products
Exosomes - Unmet Needs
Exosomes - Market Drivers and Barriers
Exosomes - Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 minutes ago
- Globe and Mail
Ball Corp Set to Report Q2 Earnings: What Lies Ahead for the Stock?
Ball Corporation BALL is scheduled to report second-quarter 2025 results on Aug. 5, before the opening bell. The Zacks Consensus Estimate for BALL's net sales is pegged at $3.15 billion, indicating 6.6% growth from the year-ago reported figure. The consensus estimate for earnings is pegged at 87 cents per share, which has moved down 1.1% in the past 60 days. The estimate indicates year-over-year growth of 17.6%. BALL's Solid Earnings Surprise History Ball Corp's earnings beat the Zacks Consensus Estimates in the trailing four quarters, the average surprise being 4.9%. What the Zacks Model Unveils for Ball Corp Our model does not conclusively predict an earnings beat for BALL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you can see below. You can uncover the best stocks before they are reported with our Earnings ESP Filter. Earnings ESP: Ball Corp has an Earnings ESP of -0.77%. Zacks Rank: BALL currently carries a Zacks Rank of 3. Factors Likely to Have Shaped BALL's Q2 Performance Ball Corp has lately been witnessing weaker-than-expected demand as customer spending has been muted amid higher retail prices, particularly in the United States. This is likely to get reflected in BALL's second-quarter results. High input and labor costs due to supply constraints are anticipated to have impacted the company's performance. However, BALL has been focused on improving its efficiency and reducing costs, which is likely to have negated these impacts and aided its margins. Our estimate for the Beverage packaging, North and Central America segment's net sales is pegged at $1.52 billion, indicating a 3.2% year-over-year rise. We expect the segment's volume to increase 2.3% year over year. We anticipate a 14.4% year-over-year slip in the segment's operating income to $180 million. Our model predicts the Beverage Packaging, Europe segment's sales to be $923 million, indicating 4.9% growth from the year-ago quarter's reported figure. We expect volume growth of 4.3% for this segment. The segment's operating income is projected at $98 million, indicating a 13.6% year-over-year dip. We expect the Beverage Packaging, South America segment's net sales to be $448 million, indicating 6.2% growth from the year-ago period's reported level. The consensus estimate for the segment's operating income is pegged at $32 million, indicating a 12.8% dip from the year-ago quarter's actual. Our model predicts a volume increase of 5.4% for the segment. BALL Stock's Price Performance The company's shares have lost 10.1% in the past year compared with the industry 's 1.9% decline. Stocks to Consider Here are some stocks with the right combination of elements to post an earnings beat in their upcoming releases. Emerson Electric Co. EMR, expected to release results on Aug. 6, currently has an Earnings ESP of +0.46% and a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here. The consensus estimate for Emerson Electric's earnings for the third quarter of fiscal 2025 is pegged at $1.51 per share, indicating year-over-year growth of 5.6%. EMR has a trailing four-quarter average surprise of 3.4%. Parker-Hannifin Corporation PH, slated to release second-quarter 2025 results on Aug. 7, has an Earnings ESP of +0.23% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for Parker-Hannifin's second-quarter 2025 earnings is pegged at $7.08 per share, suggesting a year-over-year rise of 4.6%. PH has a trailing four-quarter average surprise of 4.5%. Eaton Corporation plc ETN is scheduled to release second-quarter 2025 results on Aug. 5. It has an Earnings ESP of +0.33% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for Eaton's second-quarter 2025 earnings is pegged at $2.92 per share, suggesting a year-over-year rise of 6.9%. Eaton has a trailing four-quarter average surprise of 1.8%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Emerson Electric Co. (EMR): Free Stock Analysis Report Parker-Hannifin Corporation (PH): Free Stock Analysis Report Eaton Corporation, PLC (ETN): Free Stock Analysis Report Ball Corporation (BALL): Free Stock Analysis Report
Globe and Mail
3 minutes ago
- Globe and Mail
FLR BREAKING NEWS: Fluor Corporation Stock Plummets over 30% on Infrastructure Delays – BFA Law is Investigating and Urges Investors with Losses to Contact the Firm
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Fluor Corporation (NYSE: FLR) for potential violations of the federal securities laws. If you invested in Fluor, you are encouraged to obtain additional information by visiting: Why Is Fluor being Investigated? Fluor is a global professional services firm that provides engineering, procurement and construction, fabrication and modularization, and project management services. The Company has three principal segments: Urban Solutions, Energy Solutions and Mission Solutions. Its Urban Solutions segment includes infrastructure teams that provide a broad range of services, including consulting, design, planning, financial structuring, engineering, construction and operation and maintenance services. During the relevant period, the Company touted the strong productivity across its infrastructure portfolio. In truth, several of Fluor's infrastructure projects experienced undisclosed design errors, delays, and price escalation that significantly impacted its business. The Stock Declines as the Truth Is Revealed On August 1, 2025, before market hours, Fluor reported its fiscal Q2 2025 financial results and held an earnings call. The Company announced disappointing earnings and revealed 'a $54 million net impact of cost growth and expected recoveries on three infrastructure projects, due to subcontractor design errors, the related schedule impacts, and price escalation.' The Company also announced, 'a shift in expected capital spending from some clients.' On this news, the price of Fluor stock fell more than 30% during trading on August 1, 2025. Click here for more information: What Can You Do? If you invested in Fluor you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit
Globe and Mail
3 minutes ago
- Globe and Mail
Markel's Q2 Earnings Surpass Estimates, Premiums Rise Y/Y
Markel Group Inc. MKL reported second-quarter 2025 net operating earnings per share of $25.46, which beat the Zacks Consensus Estimate by 2.9%. However, the bottom line decreased 1.9% year over year. Markel witnessed improved earned premiums and increased net investment income. Quarterly Operational Update of MKL Total operating revenues of $4 billion beat the Zacks Consensus Estimate by 0.7%. The top line increased 4.9% year over year. Earned premiums increased 3.1% year over year to $2.1 billion in the reported quarter. The figure was higher than our estimate of $2 billion. Net investment income increased 3% year over year to $230 million in the second quarter driven by a higher yield and higher average holdings of fixed maturity securities in 2025. The figure was lower than our estimate of $263.9 million. Total operating expenses increased 6.2% to $3.5 billion, owing to higher losses and loss adjustment expenses, underwriting, acquisition and insurance expenses, product expenses, services and other expenses and amortization of acquired intangible assets. MKL's combined ratio deteriorated 280 basis points (bps) year over year to 96.3 in the reported quarter. Segment Update Markel Insurance: Earned premiums increased 2.9% year over year to $2.1 billion. Total operating revenues rose 2.9% year over year to 2.1 billion. Operating income decreased 51.3% year over year to 60.3 million. The combined ratio for the reported quarter deteriorated 310 bps to 96.9 year over was primarily due to adverse development during the year on its run-off risk-managed directors and officers product lines, as well as on its Global Reinsurance division, which the company has announced is being placed into run-off. Investing: Operating income jumped 724.1% year over year to 822.4 million. This was primarily driven by higher net investment income, net investment gains and services and other revenues. Markel Ventures: Operating revenues of $1.6 billion improved 6.5% year over year, driven by the contributions from the acquisitions of Valor and EPI, as well as improved performance at the construction services businesses. Operating income of $207.8 million increased 17% year over year Financial Update Markel exited the second quarter of 2025 with cash and cash equivalents of $3.7 billion, up 0.8% from the 2024-end level. The debt balance increased 0.8% year over year to $4.4 billion as of June 30, 2025, from the 2024-end level. Shareholders' equity was $17.3 billion as of the second quarter of 2025, up 2.4% from 2024-end. Net cash provided by operating activities was $880.5 million in the first half of 2025, down 27.18% year over year, reflecting lower net premium collections. Zacks Rank Markel currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Performance of Some Other Diversified Operators Honeywell International Inc. HON reported second-quarter 2025 adjusted earnings of $2.75 per share, which surpassed the Zacks Consensus Estimate of $2.64. The bottom line increased 10% year over year on an adjusted basis. On a reported basis, the company's earnings were $2.45 per share, up 4% year over year. Total revenues of $10.35 billion beat the consensus estimate of $10.02 billion. The top line increased 8% from the year-ago quarter, driven by strength in the Aerospace Technologies segment. Organic sales increased 5% year over year. 3M Company MMM reported second-quarter 2025 results, wherein revenues and earnings surpassed the Zacks Consensus Estimate. 3M delivered adjusted earnings of $2.16 per share, which surpassed the Zacks Consensus Estimate of $2.01. The company reported earnings of $1.93 per share in the year-ago quarter. The company reported net revenues of $6.34 billion in the quarter. The metric increased 1.4% year over year. Organic sales inched up 0.6%. Foreign currency translation had a positive impact of 0.8% while acquisitions/divestitures did not have any material impact. MMM's adjusted revenues of $6.16 billion beat the consensus estimate of $6.12 billion. On an adjusted basis, organic revenues increased 1.5% year over year. Danaher Corporation 's DHR second-quarter 2025 adjusted earnings of $1.80 per share beat the Zacks Consensus Estimate of $1.64. The bottom line increased 4.7% year over year. Danaher reported net sales of $5.94 billion, which beat the consensus estimate of $5.84 billion. The metric increased 3.5% year over year, driven by impressive performance of all the segments. DHR's core sales increased 1.5% year over year in the quarter. Foreign-currency translations had a positive impact of 2%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Honeywell International Inc. (HON): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report Markel Group Inc. (MKL): Free Stock Analysis Report
